Operational Updates News Today

CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data...

Oil Exploration Co. Releases Exciting Operational Updates

Obe-cel, a potentially transformational treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia , on track for a Biologics License Application submission to the US Food & Drug...

Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistanceRoche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of mul...

01.08.2023 - Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially ...

Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy... | May 9, 2023

Annual Revenue Increased by 534% Toronto, Ontario--(Newsfile Corp. - April 28, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics

Sunteck Realty Limited has announced key operational updates for the period Q4 & FY2022-23.

The March quarter (Q4FY23) operational updates issued by some key listed realty firms over the past few days suggest that the sector has ended FY23 on an upbeat note.

Humanitarian situation reports, response plans, news, analyses, evaluations, assessments, maps, infographics and more on Philippines